Masu bincike a Jami'ar Monash sun tsara wani sabon maganin rigakafi wanda zai iya hana takamaiman furotin a cikin jini don hana thrombosis ba tare da lahani ba.Wannan maganin rigakafi na iya hana cututtukan cututtuka na thrombosis, wanda zai iya haifar da bugun zuciya da bugun jini ba tare da ya shafi aikin clotting na jini na al'ada ba.

Ciwon zuciya da shanyewar jiki sun kasance manyan abubuwan da ke haifar da mace-mace da cututtuka a duniya.Magungunan antithrombotic na yanzu (anticoagulant) na iya haifar da rikice-rikice na zubar jini saboda suna tsoma baki tare da daskarewar jini na yau da kullun.Kashi hudu cikin biyar na marasa lafiya da ke karɓar maganin antiplatelet har yanzu suna da abubuwan da ke faruwa na zuciya da jijiyoyin jini.

Saboda haka, ba za a iya amfani da magungunan antiplatelet da ake da su ba a cikin manyan allurai.Sabili da haka, ingancin asibiti har yanzu yana da ban sha'awa, kuma jiyya na gaba yana buƙatar sake fasalin asali.

Hanyar bincike ita ce ta farko da za a tantance bambancin ilimin halitta tsakanin coagulation na al'ada da coagulation na pathological, kuma gano cewa von Willebrand factor (VWF) yana canza kaddarorin sa lokacin da aka samu thrombus mai haɗari.Binciken ya tsara wani maganin rigakafi wanda kawai yake ganowa da toshe wannan nau'in cutar ta VWF, saboda yana aiki ne kawai lokacin da gudan jini ya zama cuta.

Binciken ya bincikar halayen ƙwayoyin rigakafin VWF da ke wanzu kuma ya ƙaddara mafi kyawun halayen kowane rigakafin don ɗaure da toshe VWF a ƙarƙashin yanayin coagulation na cuta.Idan babu wani mummunan halayen, waɗannan yuwuwar rigakafin ana fara haɗa su zuwa sabon tsarin jini don hana waɗannan rikice-rikice masu yuwuwa.

A halin yanzu likitocin suna fuskantar ma'auni mai laushi tsakanin ingancin magunguna da illolin zubar jini.Na'urar rigakafin injiniya an ƙera ta musamman kuma ba za ta tsoma baki tare da coagulation na jini na yau da kullun ba, don haka ana fatan zai iya amfani da kashi mafi girma kuma mafi inganci fiye da hanyoyin kwantar da hankali.

An gudanar da wannan binciken in vitro tare da samfuran jinin ɗan adam.Mataki na gaba shine gwada ingancin antibody a cikin ƙaramin ƙirar dabba don fahimtar yadda yake aiki a cikin tsarin rayuwa mai rikitarwa kamar namu.

Magana: Thomas Hoefer et al.Yin niyya mai ƙarfi gradient kunna von Willebrand factor ta labari guda-sarkar antibody A1 yana rage haɓakar thrombus a cikin vitro, Haematologica (2020).